No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease

被引：38

作者：

Poulsen, Marianne K. ^{[1
]}

Nellemann, Birgitte ^{[1
]}

Bibby, Bo Martin ^{[2
]}

Stodkilde-Jorgensen, Hans ^{[3
]}

Pedersen, Steen B. ^{[1
]}

Gronbaek, Henning ^{[4
]}

Nielsen, Soren ^{[1
]}

机构：

[1] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Norrebrogade 44, DK-8000 Aarhus C, Denmark

[2] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark

[3] Aarhus Univ Hosp, MR Res Ctr, Skejby, Denmark

[4] Aarhus Univ Hosp, Dept Hepatol & Gastroenterol, Aarhus, Denmark

来源：

DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 10期

关键词：

hyperinsulinaemic-euglycaemic clamp; nonalcoholic fatty liver disease; resveratrol; trans-3,5,4'-trihydroxystilbene; very low-density lipoprotein triglyceride fatty acids oxidation; very low-density lipoprotein triglyceride kinetics; SUPPLEMENTATION; METABOLISM; TRIGLYCERIDE; GLUCOSE; WOMEN; RISK;

D O I：

10.1111/dom.13409

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The present study (NCT01446276, ClinicalTrials.gov) assessed long-term effects of high-dose Resveratrol (RSV) on basal and insulin-mediated very low-density lipoprotein triglyceride (VLDL-TG), palmitate and glucose kinetics, and liver fat content in men with nonalcoholic fatty liver disease (NAFLD). Participants (n = 16) were non-diabetic, upper-body obese (BMI > 28 kg/m(2), WHR > 0.9) men with NAFLD who were randomized (1:1) in a double-blinded, placebo-controlled clinical trial to either RSV or placebo (500 mg 3 times daily) for 6 months. Magnetic resonance (MR) spectroscopy, dual-X-ray absorptiometry and MR imaging assessed liver fat content and body composition, respectively. C-14-labeled VLDL-TG and H-3-labeled glucose and palmitate tracers, in combination with indirect calorimetry and breath samples, were used to assess kinetics and substrate oxidations during basal and hyperinsulinaemic euglycaemic clamp conditions. RSV did not improve either basal or insulin-mediated VLDL-TG secretion, oxidation or clearance rates, nor did it affect palmitate or glucose turnover. Likewise, no changes in body composition or liver fat content occurred following RSV compared with placebo treatment. Therefore, RSV cannot be recommended for treatment of metabolic abnormalities in NAFLD.

引用

页码：2504 / 2509

页数：6

共 15 条

[11] High-Dose Resveratrol Supplementation in Obese Men An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition [J].